Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4892536 | 0.88 | ALDH1A1 (0.54) | KDM4EHSD17B10ALDH1A1RAB9AMAPK1 | |
| SCHEMBL4898676 | 0.88 | KDM4E (0.50) | KDM4EHSD17B10ALDH1A1RAB9ANPC1 | |
| SCHEMBL4908582 | 0.84 | ALDH1A1 (0.47) | KDM4EALDH1A1RAB9A | |
| SCHEMBL4908569 | 0.84 | ALDH1A1 (0.47) | KDM4EALDH1A1RAB9A | |
| SCHEMBL4886273 | 0.81 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1RAB9ANPC1 | |
| SCHEMBL4886340 | 0.81 | TSHR (0.51) | ALDH1A1NPC1TSHRKMT2APOLB | |
| SCHEMBL14087771 | 0.79 | KMT2A (0.49) | KDM4EHSD17B10ALDH1A1RAB9ANPC1 | |
| SCHEMBL4893712 | 0.78 | MEN1 (0.45) | KDM4EALDH1A1MAPK1KMT2APOLB | |
| SCHEMBL4889525 | 0.75 | SMN1; SMN2 (0.44) | ALDH1A1RAB9AMAPK1TSHR | |
| SCHEMBL4883902 | 0.75 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008098859-A1 | HCV POLYMERASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | KDM4E 2519/4885HSD17B10 240/4885ALDH1A1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.